MediWound Ltd M8W
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 1.98
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 88
- Website
- https://www.mediwound.com
Comparables
Valuation
|
Metric
|
M8W
|
PTGX
|
NVCT
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 13.68 | — |
Price/Book Value | 7.11 | 3.49 | 8.86 |
Price/Sales | 1.98 | 6.36 | — |
Price/Cash Flow | — | 10.46 | — |
Price/Earnings
M8W
PTGX
NVCT
Financial Strength
|
Metric
|
M8W
|
PTGX
|
NVCT
|
|---|---|---|---|
Quick Ratio | 1.83 | 15.61 | 3.42 |
Current Ratio | 1.98 | 15.72 | 3.46 |
Interest Coverage | −1.65 | — | — |
Quick Ratio
M8W
PTGX
NVCT
Profitability
|
Metric
|
M8W
|
PTGX
|
NVCT
|
|---|---|---|---|
Return on Assets (Normalized) | −19.11% | 51.28% | −86.91% |
Return on Equity (Normalized) | −40.27% | 56.32% | −117.74% |
Return on Invested Capital (Normalized) | −25.32% | 51.24% | −123.11% |
Return on Assets
M8W
PTGX
NVCT
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Bbyrdzyvh | Gxgscs | $124.1 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Jcrlwwpq | Sxdfyx | $114.2 Bil | |||
| Moderna Inc
MRNA
| Wzjfxybn | Lfgg | $53.7 Bil | |||
| argenx SE ADR
ARGX
| Vrclyfww | Mnx | $23.0 Bil | |||
| BioNTech SE ADR
BNTX
| Mjmxdryd | Nkk | $22.2 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Zrdfhthg | Xpxth | $20.3 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Bkyzdmj | Snhfqmh | $15.9 Bil | |||
| United Therapeutics Corp
UTHR
| Bttsvqyz | Cqjp | $12.8 Bil | |||
| Incyte Corp
INCY
| Sxhjsryb | Ygwpxxm | $12.2 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Mybnjqndb | Hjtqbw | $12.2 Bil |